tefinostat
Small moleculeexperimental
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2008 (NCT00820508)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Histone deacetylase 2INHIBITOR
HDAC2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(CCCCCCC(=O)Nc1ccc(CN[C@H](C(=O)OC2CCCC2)c2ccccc2)cc1)NO- Mol. weight
- 495.62 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297582 ↗
Also known as
- chr 2845
- chr-2845
- chr-2845
- tefinostat
- tefinostat
- tefinostat
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02759601 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2012 | Chroma Therapeutics, University of London |
| NCT00820508 | Phase 1 | Dec 1, 2008 | Chroma Therapeutics, Erasmus University Rotterdam, Free University of Amsterdam, Institut Paoli-Calmettes, ZNA Stuivenberg |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chroma Therapeutics | For profit | 2 | 1 | 2 | 2008 |
| Erasmus University Rotterdam | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Free University of Amsterdam | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Institut Paoli-Calmettes | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2012 |
| ZNA Stuivenberg | Academic/Hospital | 1 | 0 | 1 | 2008 |
6 organizations
Page 1 / 1